Ticker League

EBITDA Margin for Quest Diagnostics (DGX)

As of · Reported

Metric

TTM

17.6%

YoY change

+0.70pp

Trough year (1996)

-31.1%

Peak year (2021)

29.3%

EBITDA Margin history chart for Quest Diagnostics (DGX) from 1996 to 2025

Latest: 19.9%

EBITDA Margin change chart for Quest Diagnostics (DGX) from 1996 to 2025

Latest: +0.70pp

EBITDA Margin history table for Quest Diagnostics (DGX) from 1996 to 2025

  • 202519.9%+0.70pp
  • 202419.2%+0.47pp
  • 202318.7%+0.30pp
  • 202218.4%-10.87pp
  • 202129.3%+3.73pp
  • 202025.5%+5.03pp
  • 201920.5%+1.87pp
  • 201818.6%-0.21pp
  • 201718.8%-0.83pp
  • 201619.7%-1.07pp
  • 201520.8%+3.21pp
  • 201417.5%-7.55pp
  • 201325.1%+4.46pp
  • 201220.6%+3.29pp
  • 201117.3%-4.18pp
  • 201021.5%-0.36pp
  • 200921.9%+1.18pp
  • 200820.7%+0.88pp
  • 200719.8%-1.32pp
  • 200621.1%-0.36pp
  • 200521.5%+1.03pp
  • 200420.5%+0.41pp
  • 200320.1%+2.44pp
  • 200217.6%+2.21pp
  • 200115.4%+2.20pp
  • 200013.2%+2.20pp
  • 199911.0%-0.17pp
  • 199811.2%+1.30pp
  • 19979.9%+40.95pp
  • 1996-31.1%—

EBITDA Margin values are taken from Quest Diagnostics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA Margin at Quest Diagnostics (DGX)

According to Quest Diagnostics's latest reported financial statements, the company's latest reported EBITDA margin is 17.6%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Quest Diagnostics (DGX) most recent annual EBITDA margin stands at 19.88% (2025) – expanded 0.7 percentage points year-over-year.

2021 marks the peak EBITDA margin at 29.28%, with the historical low of -31.07% recorded in 1996.

Quest Diagnostics EBITDA Margin by Year

Quest Diagnostics EBITDA Margin 2025: 19.9%

In 2025, Quest Diagnostics reported EBITDA margin of 19.88%, expanded 0.7 percentage points from 2024.

Quest Diagnostics EBITDA Margin 2024: 19.2%

Quest Diagnostics EBITDA margin in 2024 was 19.19%, expanded 0.5 percentage points from 2023.

Quest Diagnostics EBITDA Margin 2023: 18.7%

2023's EBITDA margin for Quest Diagnostics came in at 18.72%, expanded 0.3 percentage points from 2022.

Quest Diagnostics EBITDA Margin 2022: 18.4%

Quest Diagnostics posted EBITDA margin of 18.42% in 2022, contracted 10.9 percentage points from 2021.

Quest Diagnostics EBITDA Margin 2021: 29.3%

Quest Diagnostics EBITDA margin in 2021 was 29.28%.

See more financial history for Quest Diagnostics (DGX).

Sector peers by EBITDA Margin

Healthcare peers of Quest Diagnostics (DGX), ranked by their latest EBITDA margin

Frequently asked questions

Quest Diagnostics (DGX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview